EDAP Schedules Webcast and Conference Call for First Quarter 2013 Results
2013年5月14日 - 3:45AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today details relating to its first quarter
2013 results announcement, which will take place on Thursday, May
16, 2013, before the opening of the market.
EDAP will hold a conference call on Thursday, May 16, 2013 at
8:30 a.m. EDT to discuss the results. The dial-in numbers are
1-877-300-8521 for domestic callers and 1-412-317-6026 for
international callers. The conference ID number for both is
10029077. A live webcast of the conference call will be
available online from the investor relations page of the Company's
corporate website at www.edap-tms.com.
After the live webcast, the call will remain available on EDAP's
website, www.edap-tms.com, through June 13, 2013. In
addition, a telephonic replay of the call will be available until
May 26, 2013. The replay dial-in numbers are 1-877-870-5176
for domestic callers and 1-858-384-5517 for international
callers. Please use event passcode 10029077.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) treatment of localized prostate cancer. HIFU
treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized
prostate cancer (stages T1-T2) who are not candidates for surgery
or who prefer an alternative option, or for patients who failed
radiotherapy treatment., Ablatherm-HIFU is approved and
commercialized in Europe as a treatment for prostate cancer and is
currently under regulatory review in the U.S. following submission
of the Pre-Market Approval Application in February 2013 after the
completion of a multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA.
The Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment (the Sonolith® range)
for treatment of urinary tract stones using extra-corporeal
shockwave lithotripsy (ESWL). For more information on the Company,
please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements that involve risks and
uncertainties. Such statements are based on management's current
expectations and are subject to a number of uncertainties,
including the uncertainties of the regulatory process, and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical
trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 6 2024 まで 7 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 7 2023 まで 7 2024